Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

NCT07612267 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07612267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Recruiting
Start date
August 5, 2026
Completion date
September 30, 2028
Enrollment
14 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel disease, lactation